BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data – Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in...

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...